Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages

DNA and Cell Biology

Volumn 23, Issue 5, 2004, Pages 283-292

  Rival, Yves ^a   Benéteau, Nathalie ^a   Chapuis, Violaine ^a   Taillandier, Thierry ^a   Lestienne, Fabrice ^a   Dupont Passelaigue, Elisabeth ^a   Patoiseau, Jean François ^a   Colpaert, Francis C ^a   Junquéro, Didier ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AVASIMIBE; CARDIOVASCULAR AGENT; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; FENOFIBRIC ACID; FLUINDOSTATIN; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVALONIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIRINIXIC ACID; ROSIGLITAZONE;

ARTICLE; CONCENTRATION RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; HUMAN CELL; IMMUNOASSAY; MACROPHAGE; MONOCYTIC LEUKEMIA; PRIORITY JOURNAL;

ACETATES; ANILIDES; CARDIOVASCULAR AGENTS; CELL LINE; ENZYME INHIBITORS; FATTY ACIDS, MONOUNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; LIPOPROTEINS, LDL; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MEVALONIC ACID; MONOCYTES; PROCETOFEN; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; STEROL O-ACYLTRANSFERASE; SULFONIC ACIDS; TETRADECANOYLPHORBOL ACETATE; THIAZOLIDINEDIONES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSCRIPTION FACTORS;

EID: 2542612877     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454904323090912     Document Type: Article

References (36)

1. AIKAWA, M., RABKIN, E., OKADA, Y., VOGLIC, S.J., CLINTON, S.K., BRINCKERHOFF, C.E., SUKHOVA, G.K., and LIBBY, P. (1998). Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization. Circulation 97, 2433-2444.
2. BELLOSTA, S., CANAVESI, M., FAVARI, E., COMINACINI, L., GAVIRAGHI, G., FUMAGALLI, R., PAOLETTI, R., and BERNINI, F. (2001). Lacidipine modulates the secretion of matrix metalloproteinase-9 by human macrophages. J. Pharmacol. Exp. Ther. 296, 736-743.
3. BELLOSTA, S., VIA, D., CANAVESI, M., PFISTER, P., FUMAGALLI, R., PAOLETTI, R., and BERNINI, F. (1998). HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. 18, 1671-1678.
4. BENDECK, M.P., IRVIN, C., and REIDY, M.A. (1996). Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ. Res. 78, 38-43.
5. CASTRILLO, A., JOSEPH, S.B., MARATHE, C., MANGELSDORF, D.J., and TONTONOZ, P. (2003). Liver X receptor dependent repression of matrix metalloproteinase-9 expression in macrophages. J. Biol. Chem. 278, 10443-10449.
6. CHASE, A.J., BOND, M., CROOK, M.F., and NEWBY, A.C. (2002). Role of nuclear factor-kB activation in metalloproteinase-1, -3, and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler. Thromb. Vasc. Biol. 22, 765-771.
7. DOLLERY, C.M., MCEWAN, J.R., and HENNEY, A.M. (1995). Matrix metalloproteinases and cardiovascular disease. Circ. Res. 77, 863-868.
8. DUCHARME, A., FRANTZ, S., AIKAWA, M., RABKIN, E., LINDSEY, M., ROHDE, L.E., SCHOEN, F.J., KELLY, R.A., WERB, Z., LIBBY, P., et al. (2000). Targeted deletion of matrix metalloproteinases-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest. 106, 55-62.
9. EBERHARDT, W., AKOOL, EL.S., REBHAN, J., FRANK, S., BECK, K.F., FRANZEN, R., HAMADA, F.M.A., and PFEILSCHIFTER, J. (2002). Inhibition of cytokine-induced matrix metalloproteinase 9 expression by peroxisome proliferator-activated receptor α agonists is indirect and due to a NO-mediated reduction of mRNA stability. J. Biol. Chem. 277, 33518-33528.
10. FALK, E., SHAH, P.K., and FUSTER, V. (1995). Coronary plaque disruption. Circulation 92, 657-671.
11. GAN, X., WONG, B., WRIGHT, S.D., and CAI, T.Q. (2001). Production of matrix metalloproteinase-9 in CaCO-2 cells in response to inflammatory stimuli. J. Interferon Cytokine Res. 21, 93-98.
12. HAFFNER, S.M., GREENBERG, A.S., WESTON, W.M., CHEN, H., WILLIAMS, K., and FREED, M.I. (2002). Effect of rosiglitazone treatment on non traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106, 679-684.
13. HANSEN, J.B., ZHANG, H., RASMUSSEN, T.H., PETERSEN, R.K., FLINDT, E.N., and KRISTIANSEN, K. (2001). Peroxisome proliferator-activated receptor delta (PPARdelta)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. J. Biol. Chem. 276, 3175-3182.
14. JIANG, C., TING, A.T., and SEED, B. (1998). PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86.
15. JOSEPH, S.B., CASTRILLO, A., LAFITTE, B.A., MANGELSDORF, D.J., and TONTONOZ, P. (2003). Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9, 213-219.
16. KLEINER, D.E., and STETLER-STEVENSON, W.G. (1994). Quantitative zymography: Detection of picogram, quantities of gelatinases. Anal. Biochem. 218, 325-329.
17. LESSNITZER, L.M., PARKS, D.J., BLEDSOE, R.K., COBB, J.E., COLLINS, J.L., CONSLER, T.G., DAVIS, R.G., HULL-RYDE, E.A., LENHARD, J.M., PATEL, L., et al. (2002). Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41, 6640-6650.
18. LI, A.C., BROWN, K.K., SILVESTRE, M.J., WILLSON, T.M., PALINSKI, W., and GLASS, C.K. (2000). Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106, 523-531.
19. LIBBY, P., and AIKAWA, M. (1998). New insights into plaque stabilisation by lipid lowering. Drugs 56, 9-13.
20. LUAN, Z., CHASE, A.J., and NEWBY, A.C. (2003). Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler. Thromb. Vasc. Biol. 23, 769-776.
21. MARX, N., SCHÖNBECK, U., LAZAR, M.A., LIBBY, P., and PLUTZKY, J. (1998a). Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 83, 1097-1103.
22. MARX, N., SUKHOVA, G., MURPHY, C., LIBBY, P., and PLUTZKY, J. (1998b). Macrophages in human atheroma contain PPARγ. Differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro. Am. J. Pathol. 153, 17-23.
23. MUKHERJEE, R. (2002). PPARs: Versatile targets for future therapy for obesity, diabetes and cardiovascular diseases. Drug News Perspect. 15, 261-267.
24. OLIVER, W.R., JR., SHENK, J.L., SNAITH, M.R., RUSSELL, C.S., PLUNKET, K.D., BODKIN, N.L., LEWIS, M.C., WINEGAR, D.A., SZNAIDMAN, M.L., LAMBERT, M.H., et al. (2001). A selective peroxisome-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. USA 98, 5306-5311.
25. PYO, R., LEE, J.K., SHIPLEY, J.M., CURCI, J.A., MAO, D., ZIPORIN, S.J., ENNIS, T.L., SHAPIRO, S.D., SENIOR, R.M., and THOMPSON, R.W. (2000). Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J. Clin. Invest. 105, 1641-1649.
26. RICOTE, M., LI, A.C., WILLSONS, T.M., KELLY, C.J., and GLASS, C.K. (1998). The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391, 79-82.
27. RIVAL, Y., BENÉTEAU, N., TAILLANDIER, T., PEZET, M., DUPONT-PASSELAIGUE, E., PATOISEAU, J.F., JUNQUERO, D., COLPAERT, F.C., and DELHON, A. (2002a). PPARα and PPARδ inhibitors inhibit cytokine-induced nuclear translocation of NF-kB and expression of VCAM-1 in EAhy926 endothelial cells. Eur. J. Pharmacol. 435, 143-151.
28. RIVAL, Y., JUNQUERO, D., BRUNIQUEL, F., N'GUYEN, X., FAURÉ, P., POMIÈS, J.P., DEGRYSE, A.D., and DELHON, A. (2002b). Anti-atherosclerotic properties of the Acyl-coenzyme A: Cholesterol Acyltransferase Inhibitor F12511 in casein-fed new Zealand rabbits. J. Cardiol. Pharmacol. 39, 181-191.
29. SHU, H., WONG, B., ZHOU, G., LI, Y., BERGER, J., WOODS, J.W., WRIGHT, S.D., and CAI, T.Q. (2000). Activation of PPARα or -γ reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem. Biophys. Res. Commun. 267, 345-349.
30. TAJIRIAN, T., DENNIS, J.W., and SWALLOW, C.J. (2000). Regulation of human monocyte proMMP-9, production by fetuin, an endogenous TGF-β antagonist. J. Cell. Physiol. 185, 174-183.
31. WEITZ-SCHMIDT, G. (2002). Statins as anti-inflammatory agents. Trends Pharmacol. Sci. 23, 482-486.
32. WILLSON, T.M., BROWN, P.J., STERNBACH, D.D., and HENKE, B.R. (2000). The PPARs: From orphan receptors to drug discovery. J. Med. Chem. 43, 527-550.
33. WINBERG, J.O., KOLSET, S.O., BERG, E., and UHLIN-HANSEN, L. (2000). Macrophages secrete matrix metalloproteinase 9 covalently linked to the core protein of chondroitin sulphate proteoglycans. J. Mol. Biol. 304, 669-680.
34. XIE, B., LAOUAR, A., and HUBERMAN, E. (1998). Fibronectin-mediated cell adhesion is required for induction of 92-kDa type IV collagenase/gelatinase (MMP-9) gene expression during macrophage differentiation. The signalling role of protein kinase C-beta. J. Biol. Chem. 273, 11576-11582.
35. YOO, H.G., SHIN, B.A., PARK, J.S., LEE, K.H., CHAY, K.O., YANG, S.Y., AHN, B.W., and JUNG, Y.D. (2002). IL-1β induces MMP-9 via reactive oxygen species and NF-κB in murine macrophage RAW 264.7 cells. Biochem. Biophys. Res. Commun. 298, 251-256.
36. ZEMPO, N., KOYAMA, N., KENAGY, R.D., LEA, H.J., and CLOWES, A.W. (1996). Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler. Thromb. Vasc. Biol. 16, 28-33.